2012, ISBN: 9782817803357
[ED: Hardcover], [PU: Springer / Springer Paris / Springer, Berlin], Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but als… Plus…
booklooker.de buecher.de GmbH & Co. KG Frais d'envoiVersandkostenfrei, Versand nach Deutschland. (EUR 0.00) Details... |
Biosimilars | A New Generation of Biologics | Jean-Louis Prugnaud (u. a.) | Buch | Englisch | 2012 | Springer Paris | EAN 9782817803357 - edition reliée, livre de poche
2012, ISBN: 9782817803357
[ED: Gebunden], [PU: Springer Paris], Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high … Plus…
booklooker.de |
Biosimilars / A New Generation of Biologics / Jean-Louis Prugnaud (u. a.) / Buch / Englisch / 2012 / Springer Paris / EAN 9782817803357 - edition reliée, livre de poche
2012, ISBN: 9782817803357
[ED: Gebunden], [PU: Springer Paris], Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high … Plus…
booklooker.de |
Biosimilars A New Generation of Biologics Jean-Louis Prugnaud (u. a.) Buch Englisch 2012 Springer Paris EAN 9782817803357 - edition reliée, livre de poche
2012, ISBN: 9782817803357
[ED: Gebunden], [PU: Springer Paris], Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high … Plus…
booklooker.de |
2013, ISBN: 2817803353
Gebundene Ausgabe Arznei - Arzneimittel, Medikament, Pharmaka, Tablette, Immunsystem - Immunologie - Immun - Autoimmunität, Krebs (Krankheit) / Onkologie, Onkologie - Radioonkologie, Med… Plus…
Achtung-Buecher.de MARZIES.de Buch- und Medienhandel, 14621 Schönwalde-Glien Frais d'envoiVersandkostenfrei innerhalb der BRD. (EUR 0.00) Details... |
2012, ISBN: 9782817803357
[ED: Hardcover], [PU: Springer / Springer Paris / Springer, Berlin], Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but als… Plus…
Prugnaud, Jean-Louis:
Biosimilars | A New Generation of Biologics | Jean-Louis Prugnaud (u. a.) | Buch | Englisch | 2012 | Springer Paris | EAN 9782817803357 - edition reliée, livre de poche2012, ISBN: 9782817803357
[ED: Gebunden], [PU: Springer Paris], Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high … Plus…
Biosimilars / A New Generation of Biologics / Jean-Louis Prugnaud (u. a.) / Buch / Englisch / 2012 / Springer Paris / EAN 9782817803357 - edition reliée, livre de poche
2012
ISBN: 9782817803357
[ED: Gebunden], [PU: Springer Paris], Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high … Plus…
Biosimilars A New Generation of Biologics Jean-Louis Prugnaud (u. a.) Buch Englisch 2012 Springer Paris EAN 9782817803357 - edition reliée, livre de poche
2012, ISBN: 9782817803357
[ED: Gebunden], [PU: Springer Paris], Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high … Plus…
2013, ISBN: 2817803353
Gebundene Ausgabe Arznei - Arzneimittel, Medikament, Pharmaka, Tablette, Immunsystem - Immunologie - Immun - Autoimmunität, Krebs (Krankheit) / Onkologie, Onkologie - Radioonkologie, Med… Plus…
Données bibliographiques du meilleur livre correspondant
Auteur: | |
Titre: | |
ISBN: |
Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the “generic rule” valid for small chemical entities.
In response, a dedicated regulation was issued in the European Union. It is based on the concept of “biological medicinal products similar to a biological reference product”, or “biosimilars”. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature.
This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the Eu
Informations détaillées sur le livre - Biosimilars
EAN (ISBN-13): 9782817803357
ISBN (ISBN-10): 2817803353
Version reliée
Date de parution: 20121130
Editeur: Springer Editions
87 Pages
Poids: 0,343 kg
Langue: Englisch
Livre dans la base de données depuis 2007-02-10T18:10:29+01:00 (Zurich)
Page de détail modifiée en dernier sur 2022-08-19T11:29:49+02:00 (Zurich)
ISBN/EAN: 9782817803357
ISBN - Autres types d'écriture:
2-8178-0335-3, 978-2-8178-0335-7
Autres types d'écriture et termes associés:
Auteur du livre: jean hugues, john seymour, louis
Titre du livre: leben auf dem lande
Données de l'éditeur
Auteur: Jean-Louis Prugnaud; Jean-Hugues Trouvin
Titre: Biosimilars - A New Generation of Biologics
Editeur: Springer; Springer Paris
90 Pages
Date de parution: 2012-11-21
Paris; FR
Imprimé / Fabriqué en
Poids: 0,336 kg
Langue: Anglais
128,39 € (DE)
131,99 € (AT)
142,00 CHF (CH)
POD
XVIII, 90 p.
BB; Oncology; Hardcover, Softcover / Medizin/Klinische Fächer; Onkologie; Verstehen; Biomedicine; Biosimilars; Cost; Immunogenicity; Interchangeability; Nephrology; Pharmacy; Pharmaceutical Sciences/Technology; Immunology; Oncology; Nephrology; Pharmacy; Pharmaceutics; Immunology; Nierenheilkunde, Nephrologie; Pharmazie, Apotheke; Medizinische Chemie, Pharmazeutische Chemie; Immunologie; BC; EA
Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the “generic rule” valid for small chemical entities. In response, a dedicated regulation was issued in the European Union. It is based on the concept of “biological medicinal products similar to a biological reference product”, or “biosimilars”. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature. This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context.Autres livres qui pourraient ressembler au livre recherché:
Dernier livre similaire:
9782817805146 Biosimilars (Jean-Louis Prugnaud; Jean-Hugues Trouvin)
< pour archiver...